Insys Therapeutics (NASDAQ:INSY) is scheduled to release its earnings data after the market closes on Monday, November 5th. Analysts expect Insys Therapeutics to post earnings of ($0.32) per share for the quarter.
Insys Therapeutics (NASDAQ:INSY) last issued its quarterly earnings data on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.17). Insys Therapeutics had a negative return on equity of 130.43% and a negative net margin of 238.31%. The business had revenue of $23.47 million for the quarter, compared to analysts’ expectations of $25.91 million. During the same period last year, the business earned $0.03 earnings per share. The company’s revenue for the quarter was down 44.9% on a year-over-year basis. On average, analysts expect Insys Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of INSY opened at $8.95 on Friday. Insys Therapeutics has a 1-year low of $4.88 and a 1-year high of $14.00. The company has a market cap of $618.46 million, a PE ratio of -18.27 and a beta of 1.65.
A number of brokerages recently issued reports on INSY. ValuEngine upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, August 15th. Zacks Investment Research lowered shares of Insys Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 15th. Royal Bank of Canada restated a “buy” rating and set a $9.00 target price on shares of Insys Therapeutics in a research report on Thursday, August 9th. Piper Jaffray Companies set a $4.00 target price on shares of Insys Therapeutics and gave the stock a “sell” rating in a research report on Saturday, August 11th. Finally, Jefferies Financial Group restated a “buy” rating and set a $10.00 target price on shares of Insys Therapeutics in a research report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Insys Therapeutics presently has an average rating of “Hold” and a consensus price target of $7.67.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Further Reading: Short Selling – Explanation For Shorting Stocks
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.